Skip to main content

Research Repository

Advanced Search

Role of oral teriflunomide in the management of multiple sclerosis

Tanasescu, Radu; Evangelou, Nikos; Constantinescu, Cris S.

Authors

Radu Tanasescu

Nikos Evangelou

Cris S. Constantinescu



Abstract

The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed.

Journal Article Type Article
Publication Date Apr 22, 2013
Journal Neuropsychiatric Disease and Treatment
Print ISSN 1176-6328
Electronic ISSN 1176-6328
Publisher Dove Medical Press
Peer Reviewed Peer Reviewed
Volume 9
APA6 Citation Tanasescu, R., Evangelou, N., & Constantinescu, C. S. (2013). Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 9, doi:10.2147/NDT.S31248
DOI https://doi.org/10.2147/NDT.S31248
Publisher URL http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639219/
Copyright Statement Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf

Files

ndt-9-539.pdf (424 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf





You might also like



Downloadable Citations

;